NCT01088386Enrolling by invitation
Zyprexa® Relprevv™ Patient Care Program
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 15 Mar 2010
- Start date
- Mar 2010
- Primary completion date
- Jun 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Schizophrenia
- NCT number
- NCT01088386
What you commit to
- Study type: Observational
- Planned participants: 4000
- From Mar 2010 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any patient not receiving Zyprexa Relprevv
Who the study is looking for
- Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient Care Program
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| United BioSource Corporation Coordinator of this site? Confirm its status | Blue Bell | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.